Kura Oncology, Inc. (KURA)
Nasdaq: KURA · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2008
Who owns Kura Oncology, Inc.
As filed with the SECHolders of 5% or more
5
Bvf Partners L P/il holds 9.99% of Common Stock, par value $0.0001 per share, as its SCHEDULE 13G/A filed Nov 14, 2025 says.
Directors and officers
15
report now, of 28 people on the record since 2015. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Bvf Partners L P/il
SCHEDULE 13G/A · filed Nov 14, 2025 · Common Stock, par value $0.0001 per share · 7.5% in Feb 4, 2025
Montanova Capital, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share · 9.4% in May 2, 2025
Blackrock, Inc.
SCHEDULE 13G/A · filed Oct 27, 2026 · Common Stock · 7.8% in Apr 17, 2025
State Street Corporation
SCHEDULE 13G · filed Feb 9, 2026 · COMMON STOCK
Vanguard Capital Management
SCHEDULE 13G · filed Apr 30, 2026 · Common Stock
RA Capital Management, L.P.
SCHEDULE 13G/A · filed May 15, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
EcoR1 Capital, LLC
SCHEDULE 13G/A · filed Aug 14, 2025 · Common Stock · reported falling below 5%
Armistice Capital, LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.67% in Feb 17, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
Paradigm BioCapital Advisors LP
SCHEDULE 13G/A · filed Feb 14, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%
Deerfield Mgmt, L.P.
SCHEDULE 13G/A · filed Feb 13, 2025 · Common Stock · reported falling below 5%
What KURA reports owning in othersstakes of 5% or more, and other ties
Kura Oncology, Inc. reports no stake in another company in the record.
Insider tradesForm 4
40sales
2purchases
12sales on a scheduled plan
7people selling
$3.8Msold, in dollars
$2.4Mbought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 29 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Leoni Mollie | Chief Medical Officer | 8 | $1.5M | 1 | 0 | $0 |
| Bair Teresa Brophy | Chief Legal Officer | 7 | $700,000 | 4 | 0 | $0 |
| Powl Brian T. | Chief Commercial Officer | 9 | $700,000 | 3 | 0 | $0 |
| Burrows Francis | Chief Scientific Officer | 3 | $500,000 | 0 | 0 | $0 |
| Ford Kathleen | Chief Operating Officer | 5 | $200,000 | 4 | 0 | $0 |
| Doyle Thomas James | SVP, Finance & Accounting | 7 | $200,000 | 0 | 0 | $0 |
| Hasnain Faheem | director | 1 | $100,000 | 0 | 0 | $0 |
| Wilson Troy Edward | President and CEO | 0 | $0 | 0 | 2 | $2.4M |